A clinical trial now underway is looking at whether blood plasma donated by people recovered from 2019 coronavirus disease (COVID-19) could be used to treat other people with the pandemic virus.
University of Colorado Cancer Center study of early-phase clinical trials finds variations in reporting of drug side effects, potentially obscuring safety.
Amid the rapidly evolving global coronavirus disease 2019 (COVID-19) pandemic that has already had profound effects on public health and medical infrastructure across the globe, many questions remain about its impact on child health.
Risk behaviors that lead to sexually transmitted disease infection or unwanted pregnancy were cut dramatically, says Prof. Vincent Guilamo-Ramos of New York University.
OU Medicine, the OU Health Sciences Center and the Oklahoma Medical Research Foundation collaborated to create a new test for COVID-19 using technology and reagents from Fluidigm Corporation, an innovative biotechnology tools provider.
Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing the effectiveness of hydroxychloroquine as a therapy to prevent infection and symptoms in individuals who have been exposed to COVID-19-positive individuals. The trial is significant because it focuses on preventing COVID-19 and does not involve individuals who are ill with infection but rather healthy individuals who have been exposed.
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to receive subsequent systemic therapies, which may have affected the survival outcome analysis. The research confirmed previous results showing talazoparib improved patient reported quality-of-life measures over available chemotherapies and had a tolerable safety profile.
MD Anderson and Ipsen have advanced a new targeted therapy into clinical trials for certain patients with lung and ovarian cancers. Details are being presented at the AACR Annual Meeting.
Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.
Researchers are now enrolling outpatients with COVID-19 for a randomized controlled trial of the effectiveness of two drug regimens – hydroxychloroquine and hydroxychloroquine with azithromycin. There is conflicting evidence on whether it works, which is why the research team at the University of Washington School of Medicine is conducting a rigorous trial to offer answers.
يواصل فيروس كورونا (SARS-CoV-2)، الفيروس الذي يسبب فيروس كورونا المستجد (كوفيد-19)، وتيرة انتشاره مسببًا أكثر من 20,000 حالة وفاة حول العالم في أقل من أربعة شهور. ولا تزال الجهود لتطوير لقاح لفيروس كورونا المستجد (كوفيد-19) قائمة، ولكن يُحتمل أن تستغرق ما بين 12 إلى 18 شهرًا.
The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial. Data will be shared virtually at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer.
Baylor Scott & White Research Institute, the research arm of Baylor Scott & White Health, is bringing clinical trials online at an unprecedented pace in response to COVID-19. A COVID-19 therapeutic task force of more than 20 multidisciplinary researchers positioned across the state of Texas has been putting their expertise in infectious disease, cardiology, immunology, molecular biology, and other specialties together to explore research opportunities for experimental prevention and treatment options and to develop investigator-initiated studies.
Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently. Results from the dose-finding study were published April 23 in JAMA Ophthalmology. The study was conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and supported by the National Eye Institute (NEI), part of the National Institutes of Health.
The highly targeted antibody may block the coronaviruses’ ability to enter human lung cells
When a large pharmaceutical company experiences a drug trial failure and then tries to refill its pipeline by licensing a product created by another firm, such a “rushed innovation” is less likely to bring a product to market than one developed under normal, less hurried conditions. That’s because the hastily drawn licensing agreement between the two organizations leads to friction that drags development work to a halt.
A UC Davis Health study found more evidence for the efficacy of behavioral intervention in treating language problems in youth with fragile X syndrome (FXS), but none for lovastatin as a treatment for FXS.
An exploratory randomized, controlled study on the safety and efficacy of either lopinavir/ritonavir (LPV/r) or Arbidol--antivirals that are used in some countries against HIV-1 and to treat influenza , respectively--as treatments for COVID-19, the disease caused by the novel coronavirus SARS-CoV-2, suggests that neither drug improves the clinical outcome of patients hospitalized with mild-to-moderate cases of the disease over supportive care.
Each year since 2008, SCT has awarded the David Sackett Trial of the Year Award to a randomized, controlled trial published (either electronically or in print) in the previous calendar year. The 2020 recipient is Pamoja Tulinde Maisha (PALM [“Together Save Lives”] in the Kiswahili language) trial.
More than 800 employees from Rutgers, Robert Wood Johnson University Hospital and University Hospital are participating in a pioneering study
An international team of scientists led by Camillo Ricordi, M.D., director of the Diabetes Research Institute and Cell Transplant Center at the University of Miami Miller School of Medicine, has been granted immediate FDA authorization for a 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells to block the life-threatening lung inflammation that accompanies severe cases of COVID-19.
Researchers from CSIRO, Australia's national science agency, have unveiled a new approach to analysing the genetic codes - or the blueprint - of the SARS-CoV-2 virus that causes COVID-19.
A clinical trial conducted by a multi-disciplinary team from Beth Israel Deaconess Medical Center has identified four novel prototypes of 3D-printed swabs that can be used for COVID-19 testing.
Yale Cancer Center announces the appointments of Thomas Prebet, M.D., Ph.D., as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program.
Convalescent plasma therapy for COVID-19 patients — an experimental approach of giving a transfusion of plasma collected from a donor who has recovered from COVID-19 to a patient with an active infection — is the focus of a new two-part research initiative at Penn Medicine. Researchers will first collect plasma from people who have recovered from their infection under a donor research protocol. The second part involves conducting clinical trials to test the safety and efficacy of giving that plasma to moderately and severely ill hospitalized patients.
COVID-19 patients in a clinical trial at Houston Methodist Hospital are responding quickly to the antiviral drug Remdesivir. Sponsored by Gilead Sciences, Houston Methodist was the fifth site in the U.S. to join the trials and the only trial site in Houston. Its clinicians are encouraged by the results.
The first COVID-19 patient in Texas has been enrolled in a stem cell therapy clinical trial for acute respiratory distress syndrome (ARDS) at The University of Texas Health Science Center at Houston (UTHealth).
A new study from the Icahn School of Medicine at Mount Sinai suggests that blood clots, especially in the lungs, may play a role in severe cases of COVID-19.
Innovation at the University of Louisville involving multiple departments at the university has led to a promising solution for the shortage of swabs in COVID-19 test kits.
A new international trial will evaluate whether the use of medications to treat high blood pressure affect outcomes among patients who are prescribed the medication and hospitalized with COVID-19. Investigators will examine whether ACEI or ARBs help to mitigate complications or lead to worse outcomes.
Penn State Health Milton S. Hershey Medical Center has begun enrolling participants in an international clinical trial evaluating an investigational antiviral drug, remdesivir, for treatment of coronavirus disease 2019 (COVID-19).
KU Medical Center is one of 60 sites across the nation that will be participating in this clinical trial, led by the Duke Clinical Research Institute.
Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.
Henry J. Klassen, MD, PhD, professor and director of the Stem Cell and Retinal Generation Program at the UCI School of Medicine, Gavin Herbert Eye Institute, and founder of jCyte, Inc., was awarded a $6.6 million dollar grant from the California Institute for Regenerative Medicine (CIRM) for a clinical trial targeting retinitis pigmentosa (RP).
The University of Chicago Medicine is launching a clinical trial to study whether blood plasma from people who have recovered from COVID-19 can be used to treat patients who are still in the hospital with severe disease symptoms.
Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab can extend life with very few side effects in this patient population.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs – hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19.
UCLA has joined a nationwide effort to study whether convalescent plasma collected from people who have recovered from COVID-19 may yield a treatment for the deadly virus.
Physician-scientists at Beth Israel Deaconess Medical Center are now enrolling patients in a clinical trial to evaluate a potential treatment of patients with COVID-19. Part of a multi-site investigation, the trial is evaluating the safety and efficacy of sarilumab, a biologic medication already approved for adults with moderately to severely active rheumatoid arthritis, for the treatment of COVID-19.
Canada institutions are pooling their scientific expertise to develop an extraordinary immunization program using passive plasma to fight COVID-19.
Bioengineers have created a blood-drawing robot that performed as well or better than technicians. The device could increase blood draw success from difficult- to-find veins and allow healthcare workers more time to treat patients.
Mount Sinai Health System is the first in the country to use an innovative allogeneic stem cell therapy in COVID-19 patients and will play a central role in developing and conducting a rigorous clinical trial for patients with severe acute respiratory distress syndrome, the breathing illness that afflicts people who have severe cases of COVID-19.
Novel 'learning while doing' clinical trial approach called REMAP helps doctors find the optimal trade-off between quickly adopting new therapies during a pandemic, such as the anti-malarial drug hydroxychloroquine, and waiting until they are tested in longer clinical trials. The trial announced today at UPMC, called UPMC-REMAP-COVID19 learns from similar trials enrolling around the world and uses artificial intelligence to quickly arrive at answers.
Washington University School of Medicine in St. Louis is launching a clinical trial for patients hospitalized with COVID-19 at Barnes-Jewish Hospital. The trial will investigate the effectiveness of different combinations of the antimalarial drugs chloroquine and hydroxychloroquine and the antibiotic azithromycin in treating ill patients infected with the novel coronavirus.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs –hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19 (infection with the novel coronavirus).
Malaria is a leading killer of children worldwide, and new drugs are needed. New research reports encouraging early clinical results with a new compound.
A new form of magnetic brain stimulation rapidly relieved symptoms of severe depression in 90% of participants in a small study conducted by researchers at the Stanford University School of Medicine.
iNO has been used for the treatment of failing lungs, but it was also found to have antiviral properties against coronaviruses.The University of Alabama at Birmingham has been selected to begin enrolling patients in an international study assessing the use of inhaled nitric oxide (iNO) to improve outcomes for COVID-19 patients with severely damaged lungs.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right